Impact of thienopyridine administration prior to primary stenting in acute myocardial infarction

Journal of Interventional Cardiology

Volumn 22, Issue 4, 2009, Pages 378-384

  Rabbani, Leroy E ^a   Iyengar, Srinivas ^a   Dangas, George D ^a   Grines, Cindy L ^b   Cox, David A ^c   Garcia, Eulogio ^d   Tcheng, James E ^e   Griffin, John J ^f   Guagliumi, Giulio ^g   Stuckey, Thomas ^h   Turco, Mark ⁱ   Stant, Jennifer ^a   Fahy, Martin ^a   Lansky, Alexandra J ^a   Mehran, Roxana ^a   Stone, Gregg W ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b WILLIAM BEAUMONT HOSPITAL   (United States)

^c Mid Carolina Cardiology   (United States)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^e DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^f Sentara Virginia Beach General Hospital   (United States)

^g OSPEDALI RIUNITI   (Italy)

^h MOSES H CONE MEMORIAL HOSPITAL   (United States)

ⁱ Doylestown Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; TICLOPIDINE; ANTITHROMBOCYTIC AGENT; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; PYRIDINE DERIVATIVE; THIENOPYRIDINE DERIVATIVE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BARE METAL STENT; BLOOD CLOT LYSIS; CARDIAC PATIENT; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY STENT; DATA BASE; DRUG EFFECT; FEMALE; FLOW RATE; HEART MUSCLE REVASCULARIZATION; HUMAN; LENGTH OF STAY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; CONFIDENCE INTERVAL; DRUG COMBINATION; DRUG ELUTING STENT; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PREOPERATIVE CARE; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; RISK; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; ANGIOPLASTY, BALLOON, CORONARY; ANTIBODIES, MONOCLONAL; ASPIRIN; CONFIDENCE INTERVALS; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; ODDS RATIO; PLATELET AGGREGATION INHIBITORS; PREOPERATIVE CARE; PYRIDINES; TIME FACTORS;

EID: 68849107287     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2009.00474.x     Document Type: Article

References (24)

1. Leon MB, Baim DS, Popma JJ, et al. Stent anticoagulation restenosis study investigators. N Engl J Med 1998 339 : 1665 1671.
2. Müller C, Büttner HJ, Petersen J, et al. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. Circulation 2000 101 : 590 593.
3. Bertrand ME, Rupprecht HJ, Urban P, et al. CLASSICS Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: The clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000 102 : 624 629.
4. Mehta SR, Yusuf S, Peters RJ, et al. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001 358 : 527 533.
5. Sabatine MS, Cannon CP, Gibson CM, et al. Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: PCI-CLARITY study. JAMA 2005 294 : 1224 1232.
6. Stone GW, Grines CL, Cox DA, et al. Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators. Comparison of angioplasty with stenting with or without abciximab, in acute myocardial infarction. N Engl J Med 2002 346 : 957 966.
7. Lansky A, Popma J. Qualitative and quantitative angiography. In Topol EJ, ed. Text-Book of Interventional Cardiology. Philadelphia, PA : WB Saunders, 1999, pp. 725 747.
8. Lev EI, Kornowski R, Vaknin-Assa H, et al. Effect of clopidogrel pretreatment on angiographic and clinical outcomes in patients undergoing primary percutaneous coronary intervention for ST-elevation acute myocardial infarction. Am J Cardiol 2008 101 : 435 439.
9. Vlaar PJ, Svilaas T, Damman K, et al. Impact of pretreatment with clopidogrel on initial patency and outcome in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: A systematic review. Circulation 2008 118 : 1828 1836.
10. Müller I, Seyfarth M, Rüdiger S, et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001 85 : 92 93. (Pubitemid 32973418)
11. Hochholzer W, Trenk D, Frundi D, et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 2005 111 : 2560 2564.
12. Wiviott SD, Braunwald E, McCabe CH, et al. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndrome. N Engl J Med 2007 357 : 2001 2015. (Pubitemid 350106708)
13. Greenbaum AB, Ohman EM, Gibson CM, et al. Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: Results of the safety, tolerability and effect on patency in acute myocardial infarction (STEP-AMI) angiographic trial. Am Heart J 2007 154 : 702 709.
14. Steinhubl SR, Badimon JJ, Bhatt DL, et al. Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease. Vasc Med 2007 12 : 113 122.
15. Klinkhardt U, Bauersachs R, Adams J, et al. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease. Clin Pharmacol Ther 2003 73 : 232 241.
16. Azar RR, Kassab R, Zoghbi A, et al. Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease. Am Heart J 2006 151 : 521.e1 521.e4.
17. Vivekananthan DP, Bhatt DL, Chew DP, et al. Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention. Am J Cardiol 2004 94 : 358 360.
18. Chew DP, Bhatt DL, Robbins MA, et al. Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am J Cardiol 2001 88 : 672 674.
19. Noll G, Luscher TF. The endothelium in acute coronary syndromes. Eur Heart J 1998 19 (Suppl C C30 C38.
20. Jakubowski A, Chlopicki S, Olszanecki R, et al. Endothelial action of thienopyridines and thienopyrimidinones in the isolated guinea pig heart. Prostaglandins Leukot Essent Fatty Acids 2005 72 : 139 145.
21. Arrebola MM, De la Cruz JP, Villalobos MA, et al. In vitro effects of clopidogrel on the platelet-subendothelium interaction, platelet thromboxane and endothelial prostacyclin production, and nitric oxide synthesis. J Cardiovasc Pharmacol 2004 43 : 74 82.
22. Heitzer T, Rudolph V, Schwedhelm E, et al. Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2006 26 : 1648 1652.
23. Steinhubl SR, Ellis SG, Wolski K, et al. Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: Data from the evaluation of platelet IIb-IIIa inhibitor for stenting (EPISTENT) trial. Circulation 2001 103 : 1403 1409. (Pubitemid 32220632)
24. Mehilli J, Kastrati A, Huber S, et al. Abciximab in patients with AMI undergoing primary PCI after clopidogrel pretreatment: Results of the randomized BRAVE-3 trial. SCAI-ACC i2 Summit-American College of Cardiology Annual Scientific Session, Chicago, IL, March-April 2008.